41 related articles for article (PubMed ID: 30846862)
1. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
Sharma A; Galimard JE; Pryce A; Bhoopalan SV; Dalissier A; Dalle JH; Locatelli F; Jubert C; Mirci-Danicar O; Kitra-Roussou V; Bertrand Y; Fagioli F; Rialland F; Biffi A; Wynn RF; Michel G; Tambaro FP; Al-Ahmari A; Tbakhi A; Furness CL; Diaz MA; Sedlacek P; Bodova I; Faraci M; Rao K; Kleinschmidt K; Petit A; Gibson B; Bhatt NS; Kalwak K; Corbacioglu S
Bone Marrow Transplant; 2024 Apr; 59(4):451-458. PubMed ID: 38225386
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.
Medeiros BC; Othus M; Fang M; Roulston D; Appelbaum FR
Blood; 2010 Sep; 116(13):2224-8. PubMed ID: 20562328
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation.
Nagler A; Labopin M; Canaani J; Niittyvuopio R; Socié G; Kröger N; Itäla-Remes M; Yakoub-Agha I; Labussière-Wallet H; Gallego-Hernanz MP; Deconinck E; Chevallier P; Finke J; Esteve J; Mohty M
Am J Hematol; 2020 Oct; 95(10):1135-1141. PubMed ID: 32530520
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
Yuasa M; Yamamoto H; Mitsuki T; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Wake A; Koike Y; Makino S; Uchida N; Taniguchi S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2262-2270. PubMed ID: 32871257
[TBL] [Abstract][Full Text] [Related]
5. Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies.
Alkhatabi HA; Alqahtani W; Alsolami R; Elaimi A; Hazzazi MS; Almashjary MN; Alkhatabi HA; Alghuthami ME; Daous YM; Yasin EB; Barefah A
Int J Gen Med; 2024; 17():37-48. PubMed ID: 38204493
[TBL] [Abstract][Full Text] [Related]
6. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.
Nagler A; Labopin M; Mielke S; Passweg J; Blaise D; Gedde-Dahl T; Cornelissen JJ; Salmenniemi U; Yakoub-Agha I; Reményi P; Socié G; van Gorkom G; Labussière-Wallet H; Huang XJ; Rubio MT; Byrne J; Craddock C; Griškevičius L; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 Jul; 58(7):791-800. PubMed ID: 37045942
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.
Rosli AA; Azlan A; Rajasegaran Y; Mot YY; Heidenreich O; Yusoff NM; Moses EJ
Clin Exp Med; 2023 Aug; 23(4):1137-1159. PubMed ID: 36229751
[TBL] [Abstract][Full Text] [Related]
8. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.
Snowden JA; Sánchez-Ortega I; Corbacioglu S; Basak GW; Chabannon C; de la Camara R; Dolstra H; Duarte RF; Glass B; Greco R; Lankester AC; Mohty M; Neven B; de Latour RP; Pedrazzoli P; Peric Z; Yakoub-Agha I; Sureda A; Kröger N;
Bone Marrow Transplant; 2022 Aug; 57(8):1217-1239. PubMed ID: 35589997
[TBL] [Abstract][Full Text] [Related]
9. The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
Yanada M
Bone Marrow Transplant; 2021 Jun; 56(6):1257-1265. PubMed ID: 33686251
[TBL] [Abstract][Full Text] [Related]
10. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.
Rimando JC; Christopher MJ; Rettig MP; DiPersio JF
J Clin Oncol; 2021 Feb; 39(5):386-396. PubMed ID: 33434062
[No Abstract] [Full Text] [Related]
11. High
D'Angiò M; Fazio G; Grioni A; Palamini S; Sala S; Galbiati M; Biondi A; Balduzzi A; Rizzari C; Cazzaniga G
Hemasphere; 2020 Oct; 4(5):e471. PubMed ID: 33163906
[No Abstract] [Full Text] [Related]
12. Modelling the Effects of MCM7 Variants, Somatic Mutations, and Clinical Features on Acute Myeloid Leukemia Susceptibility and Prognosis.
Tripon F; Iancu M; Trifa A; Crauciuc GA; Boglis A; Dima D; Lazar E; Bănescu C
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936215
[TBL] [Abstract][Full Text] [Related]
13. A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia.
Hao X; Gu M; Sun J; Cong L
J Clin Lab Anal; 2020 Feb; 34(2):e23052. PubMed ID: 31617252
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
Canaani J; Labopin M; Itälä-Remes M; Blaise D; Socié G; Forcade E; Maertens J; Wu D; Malladi R; Cornelissen JJ; Huynh A; Bourhis JH; Esteve J; Mohty M; Nagler A
Leukemia; 2019 Aug; 33(8):1944-1952. PubMed ID: 30846862
[TBL] [Abstract][Full Text] [Related]
15. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
[TBL] [Abstract][Full Text] [Related]
16. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
17. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
Grimwade D; Hills RK; Moorman AV; Walker H; Chatters S; Goldstone AH; Wheatley K; Harrison CJ; Burnett AK;
Blood; 2010 Jul; 116(3):354-65. PubMed ID: 20385793
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
Schiller GJ; Tuttle P; Desai P
Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
Brunet S; Martino R; Sierra J
Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
